CD274 and hepatocellular carcinoma: The combination of anti-PD-L1 antibody and CSF1R inhibitor could promote the infiltration of CD8+T cells and reduce the location of TAMs, which are beneficial to the HCC therapeutic effect of anti-PD-L1 antibody (18).